亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study

医学 妊娠滋养细胞肿瘤 绒毛膜癌 化疗 回顾性队列研究 内科学 队列 依托泊苷 妊娠滋养细胞疾病 养生 化疗方案 产科 妇科 肿瘤科 怀孕 妊娠期 生物 遗传学
作者
Antônio Braga,Gabriela Paiva,Ehsan Ghorani,Fernanda Freitas,Luís Guillermo Coca Velarde,Baljeet Kaur,Nick Unsworth,Jingky Lozano-Kühne,Ana Paula Vieira dos Santos Esteves,Jorge Rezende Filho,Joffre Amim,Xianne Aguiar,Naveed Sarwar,Kevin M. Elias,Neil S. Horowitz,Ross S. Berkowitz,Michael J. Seckl
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:22 (8): 1188-1198 被引量:39
标识
DOI:10.1016/s1470-2045(21)00262-x
摘要

Background Patients with gestational trophoblastic neoplasia who have an International Federation of Gynaecology and Obstetrics (FIGO) risk score of 5 or 6 usually receive non-toxic single-agent chemotherapy as a first-line treatment. Previous studies suggest that only a third of patients have complete remission, with the remaining patients requiring toxic multiagent chemotherapy to attain remission. As stratification factors are unknown, some centres offer multiagent therapy upfront, resulting in overtreatment of many patients. We aimed to identify predictive factors for resistance to single-agent therapy to inform clinicians on which patients presenting with a FIGO score of 5 or 6 are likely to benefit from upfront multiagent chemotherapy. Methods We did a multicentre, retrospective, cohort study of patients with gestational trophoblastic neoplasia presenting with a FIGO score of 5 or 6, who received treatment at three gestational trophoblastic neoplasia reference centres in the UK, Brazil, and the USA between Jan 1, 1964, and Dec 31, 2018. All patients who had been followed up for at least 12 months after remission were included. Patients were excluded if they had received a non-standard single-agent treatment (eg, etoposide); had been given a previously established first-line multiagent chemotherapy regimen; or had incomplete data for our analyses. Patient data were retrieved from medical records. The primary outcome was the incidence of chemoresistance after first-line or second-line single-agent chemotherapy. Variables associated with chemoresistance to single-agent therapies were identified by logistic regression analysis. In patient subgroups defined by choriocarcinoma histology and metastatic disease status, we did bootstrap modelling to define thresholds of pretreatment human chorionic gonadotropin concentrations and identify groups of patients with a greater than 80% risk (ie, a positive predictive value [PPV] of 0·8) of resistance to single-agent chemotherapy. Findings Of 5025 patients with low-risk gestational trophoblastic neoplasia, we identified 431 patients with gestational trophoblastic neoplasia presenting with a FIGO risk score of 5 or 6. All patients were followed up for a minimum of 2 years. 141 (40%) of 351 patients developed resistance to single-agent treatments and required multiagent chemotherapy to achieve remission. Univariable and multivariable logistic regression revealed metastatic disease status (multivariable logistic regression analysis, odds ratio [OR] 1·9 [95% CI 1·1–3·2], p=0·018), choriocarcinoma histology (3·7 [1·9–7·4], p=0·0002), and pretreatment human chorionic gonadotropin concentration (2·8 [1·9–4·1], p<0·0001) as significant predictors of resistance to single-agent therapies. In patients with no metastatic disease and without choriocarcinoma, a pretreatment human chorionic gonadotropin concentration of 411 000 IU/L or higher yielded a PPV of 0·8, whereas in patients with either metastases or choriocarcinoma, a pretreatment human chorionic gonadotropin concentration of 149 000 IU/L or higher yielded the same PPV for resistance to single-agent therapy. Interpretation Approximately 60% of women with gestational trophoblastic neoplasia presenting with a FIGO risk score of 5 or 6 achieve remission with single-agent therapy; almost all remaining patients have complete remission with subsequent multiagent chemotherapy. Primary multiagent chemotherapy should only be given to patients with metastatic disease and choriocarcinoma, regardless of pretreatment human chorionic gonadotropin concentration, or to those defined by our new predictors. Funding None. Translation For the Portuguese translation of the abstract see Supplementary Materials section.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CodeCraft的应助被酥酥采纳,获得10
17秒前
和谐如彤完成签到,获得积分10
28秒前
30秒前
酥酥发布了新的文献求助10
33秒前
甜蜜语堂完成签到,获得积分10
33秒前
111哩完成签到,获得积分10
36秒前
40秒前
zeng发布了新的文献求助10
45秒前
irene完成签到,获得积分10
46秒前
酥酥完成签到,获得积分10
47秒前
杨佳佳完成签到,获得积分10
50秒前
Noob_saibot完成签到,获得积分10
52秒前
彭于晏的应助被zeng采纳,获得10
55秒前
儒雅语雪完成签到,获得积分10
59秒前
1分钟前
Shicheng完成签到,获得积分10
1分钟前
小李老博发布了新的文献求助10
1分钟前
ZZzz完成签到 ,获得积分10
1分钟前
酷波er的应助被科研通管家采纳,获得10
1分钟前
fantasy的应助被科研通管家采纳,获得10
1分钟前
小李老博完成签到,获得积分10
1分钟前
1分钟前
Noob_saibot关注了科研通微信公众号
1分钟前
忐忑的烤鸡完成签到,获得积分10
1分钟前
复杂曼荷完成签到,获得积分10
1分钟前
杨佳佳发布了新的文献求助10
1分钟前
juaner发布了新的文献求助10
2分钟前
2分钟前
残月初升完成签到,获得积分10
2分钟前
顺心的一德完成签到,获得积分10
2分钟前
阔达之卉完成签到 ,获得积分10
2分钟前
虚幻的霸完成签到,获得积分10
2分钟前
flyingpig发布了新的文献求助30
2分钟前
2分钟前
zeng发布了新的文献求助10
3分钟前
冷傲的夜白完成签到,获得积分10
3分钟前
汉堡包的应助被ADAB0002采纳,获得10
3分钟前
奔跑的应助被zeng采纳,获得10
3分钟前
飞快的涵柳完成签到,获得积分10
3分钟前
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166132
求助须知:如何正确求助?哪些是违规求助? 9559433
关于积分的说明 21750361
捐赠科研通 7756990
什么是DOI,文献DOI怎么找? 3429119
关于科研通互助平台的介绍 2553436
邀请新用户注册赠送积分活动 2473781